Marksans Pharma Limited (IN:MARKSANS)
:MARKSANS
MARKSANS Stock Chart & Stats
₹182.05
-₹6.40(-2.21%)
At close: 4:00 PM EST
₹182.05
-₹6.40(-2.21%)
Day’s Range― - ―
52-Week Range₹155.50 - ₹270.60
Previous CloseN/A
Volume681.00K
Average Volume (3M)99.03K
Market Cap
₹76.13B
Enterprise Value₹74.65B
Total Cash (Recent Filing)₹6.71B
Total Debt (Recent Filing)₹3.32B
Price to Earnings (P/E)18.0
Beta1.56
Next Earnings
Jun 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.44%
Share Statistics
EPS (TTM)2.50
Shares Outstanding453,163,760
10 Day Avg. Volume119,310
30 Day Avg. Volume99,030
Financial Highlights & Ratios
PEG Ratio1.24
Price to Book (P/B)4.08
Price to Sales (P/S)3.83
P/FCF Ratio298.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)10.27
Revenue Forecast (FY)₹32.32B
Bulls Say, Bears Say
Bulls Say
Revenue & Margin ExpansionSustained top-line growth (≈20.45%) alongside a high gross margin (56.38%) and improved net margin (≈14.51%) indicates effective pricing and cost control across products. This combination supports durable profitability as the company scales and absorbs fixed manufacturing costs.
Low Financial LeverageA capital structure with very low debt (D/E ~0.13) and a strong equity base (≈76% equity ratio) provides financial flexibility, reduces interest burden and recession vulnerability, and enables funding of organic growth or selective investments without stressing solvency metrics.
Diversified Product And Market ExposureA business model spanning finished-dosage generics, OTC products, domestic branded generics and regulated-market exports reduces concentration risk. Access to regulated markets and contract manufacturing relationships supports higher-margin opportunities and durable revenue diversification.
Bears Say
Weak Operating Cash ConversionOperating cash flow declining ~10% and an OCF-to-net-income ratio around 0.54 point to weaker cash conversion of reported profits. Persistently low conversion pressures liquidity for working capital, capex and shareholder returns and can constrain durable reinvestment capacity.
EPS DeclineNegative EPS growth despite revenue expansion suggests per-share performance is under pressure from dilution, margin shifts or non-operational items. If persistent, falling EPS can impair long-term shareholder returns and signal underlying profit allocation or capital structure issues.
OCF Vs FCF DisconnectA large rise in FCF alongside declining operating cash flow indicates cash improvements may stem from non‑operational items, timing or financing changes rather than steady operating performance. That disconnect raises concerns about the sustainability of cash generation.
Marksans Pharma Limited News
MARKSANS FAQ
What was Marksans Pharma Limited’s price range in the past 12 months?
Marksans Pharma Limited lowest stock price was ₹155.50 and its highest was ₹270.60 in the past 12 months.
What is Marksans Pharma Limited’s market cap?
Marksans Pharma Limited’s market cap is ₹76.13B.
When is Marksans Pharma Limited’s upcoming earnings report date?
Marksans Pharma Limited’s upcoming earnings report date is Jun 01, 2026 which is in 60 days.
How were Marksans Pharma Limited’s earnings last quarter?
Marksans Pharma Limited released its earnings results on Feb 05, 2026. The company reported ₹2.5 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.5.
Is Marksans Pharma Limited overvalued?
According to Wall Street analysts Marksans Pharma Limited’s price is currently Overvalued.
Does Marksans Pharma Limited pay dividends?
Marksans Pharma Limited pays a Annually dividend of ₹0.8 which represents an annual dividend yield of 0.44%. See more information on Marksans Pharma Limited dividends here
What is Marksans Pharma Limited’s EPS estimate?
Marksans Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marksans Pharma Limited have?
Marksans Pharma Limited has 453,163,760 shares outstanding.
What happened to Marksans Pharma Limited’s price movement after its last earnings report?
Marksans Pharma Limited reported an EPS of ₹2.5 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.555%.
Which hedge fund is a major shareholder of Marksans Pharma Limited?
Currently, no hedge funds are holding shares in IN:MARKSANS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marksans Pharma Limited
Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―
Laurus Labs Ltd.
―